Neutralizing human monoclonal antibody 8D6 against HCV infection

US10888615B2 · kind B2 · utility

Assignee

• SUZHOU GALAXY BIOPHARMA, CO., LTD. · CN

Inventors

• Honglin ZHOU · 安丰镇, CN
• Jie Liu · Houston, US
• Xin Dong · Newark, US
• Bing Sun · Shanghai, CN
• Jiangjun Wang · Shanghai, CN
• Zhiyang Ling · Shanghai, CN
• Chunyan Yi · Shanghai, CN
• Chao Bian · Shanghai, CN

Key dates

• Filing date: Apr 21, 2017
• Grant date: Jan 12, 2021
• Expiry date: Apr 21, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/186
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Provided herein is a human monoclonal antibody 8D6 against hepatitis C virus (HCV) infection. The antibody binds to the E2 subunit of HCV capsid protein, and can prevent HCV from infecting susceptible host cells. By using the antibody variable region gene or the complementary determining region (CDR) gene, different forms of genetic engineering antibodies have been transformed and produced in any expression system of the prokaryotic and eukaryotic cells as therapeutics to prevent or treat HCV infection.